Overview
flowchart TD
Metabolic_Therapy_for_Neurodeg["Metabolic Therapy for Neurodegeneration"]
Metabolic_Therapy_for_Neurodeg["table"]
Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg
style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000
Metabolic_Therapy_for_Neurodeg["class"]
Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg
style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000
Metabolic_Therapy_for_Neurodeg["infobox"]
Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg
style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000
style Metabolic_Therapy_for_Neurodeg fill:#4fc3f7,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Metabolic Therapy for Neurodegeneration</th> </tr> <tr> <td class="label">Compound</td> <td>Dose</td> </tr> <tr> <td class="label">AC-1202 (AXONA)</td> <td>20-30g daily</td> </tr> <tr> <td class="label">Ketone ester</td> <td>25-50g daily</td> </tr> <tr> <td class="label">MCT oil</td> <td>20-60g daily</td> </tr> <tr> <td class="label">Trial</td> <td>Intervention</td> </tr> <tr> <td class="label">NCT00670146</td> <td>Ketogenic diet</td> </tr> <tr> <td class="label">NCT02531438</td> <td>MCT oil (Axona)</td> </tr> <tr> <td class="label">NCT03400124</td> <td>Ketone ester</td> </tr> <tr> <td class="label">NCT04237411</td> <td>Fasting mimetic</td> </tr> <tr> <td class="label">Trial</td> <td>Intervention</td> </tr> <tr> <td class="label">NCT03963206</td> <td>Ketogenic diet</td> </tr> <tr> <td class="label">NCT05237505</td> <td>MCT supplementation</td> </tr> <tr> <td class="label">NCT05485640</td> <td>Metabolic modulator</td> </tr> </table>
Metabolic therapy encompasses therapeutic approaches that target metabolic dysfunction in neurodegenerative diseases. These strategies aim to improve brain energy metabolism, enhance mitochondrial function, and correct metabolic deficits that contribute to neuronal dysfunction and death. Key approaches include ketogenic diets, metabolic modulators, glucose metabolism enhancers, and fasting mimetics. This therapy is particularly relevant for Alzheimer's disease (AD) and Parkinson's disease (PD), both of which exhibit well-documented metabolic impairments. [@henderson2009]
Mechanism of Action
Neurodegenerative diseases are characterized by impaired cerebral glucose metabolism: [@krikorian2012]
Alzheimer's Disease : Regional brain hypometabolism (especially in posterior cingulate and hippocampus) precedes clinical symptoms by decades. Insulin resistance and impaired glucose transport contribute to energy deficits.
Parkinson's Disease : Complex I deficiency in mitochondria leads to impaired oxidative phosphorylation and ATP depletion in dopaminergic [neurons](/entities/neurons).
Ketone Utilization : Provide alternative fuel (β-hydroxybutyrate) to glucose-deficient neurons
Mitochondrial Function : Enhance electron transport chain efficiency and ATP production
Insulin Sensitization : Improve insulin signaling and glucose uptake in the brain
Oxidative Stress Reduction : Decrease [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production
Neuroinflammation Modulation : Reduce inflammatory responses through metabolic pathways
[Autophagy](/entities/autophagy) Enhancement : Activate metabolic pathways that clear misfolded proteins
Therapeutic Approaches
Ketogenic Diet and Ketone Supplementation The ketogenic diet (KD) mimics fasting metabolism by shifting energy production from glucose to ketone bodies: [@pawelzik2022]
Classic Ketogenic Diet : 70-80% fat, 15-20% protein, 5-10% carbohydrate
Medium-Chain Triglyceride (MCT) Oil : Directly produces ketones in the liver
Exogenous Ketones : Beta-hydroxybutyrate (BHB) supplements
Dichloroacetate (DCA) : Activates pyruvate dehydrogenase complex
Metformin : AMPK activator; improves insulin sensitivity
Thiazolidinediones : PPAR-γ agonists for metabolic regulation
Fasting and Fasting Mimetics
Intermittent Fasting : 16:8 or 5:2 protocols
Caloric Restriction : 20-30% reduction in daily calories
Rapamycin : [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor with fasting-like effects
Resveratrol : SIRT1 activator
Clinical Evidence
Alzheimer's Disease
Parkinson's Disease
Key Findings
Ketogenic interventions show consistent cognitive/motor improvements
Benefits may be more pronounced in patients without APOE4 allele
Adherence is challenging; dropout rates of 20-40% in studies
Metabolic biomarkers (ketone levels, glucose metabolism) correlate with clinical response
Effective patient selection requires metabolic profiling:
Fasting Ketone Levels : Baseline β-hydroxybutyrate < 0.3 mM indicates potential responsiveness
Insulin Sensitivity : HOMA-IR score for metabolic flexibility
[APOE](/proteins/apoe) Status : APOE4 carriers may respond less to glucose-based therapies
Brain Glucose Metabolism : FDG-PET showing hypometabolism patterns
Ketone Response Test : Measure BHB levels after MCT challenge
Safety and Considerations
Ketogenic Diet Risks
Hyperlipidemia : Monitor cholesterol and triglycerides
Kidney Stones : Increased risk; maintain hydration
Nutrient Deficiencies : Supplement vitamins and minerals
Acidosis : Rare in adults; monitor pH and electrolytes
Contraindications
Pancreatitis
Liver failure
Severe renal disease
History of eating disorders
Porphyria
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Ketogenic Diet](/therapeutics/ketogenic-diet)
[Mitochondrial Therapeutics](/therapeutics/mitochondrial-therapeutics)
[Caloric Restriction Mimetics](/therapeutics/caloric-restriction-mimetics)
[Metabolic Syndrome](/mechanisms/metabolic-syndrome-neurodegeneration)
External Links
[PubMed: Metabolic Therapy Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ketogenic+alzheimer+parkinson)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[Charlie Foundation - Ketogenic Diet Resources](https://charliefoundation.org/)
References
[Henderson et al., Study of the Ketogenic Agent AC-1202 (2009) (2009)](https://doi.org/10.1016/j.nut.2009.04.007)
[Krikorian et al., Ketogenic diet for MCI (2012) (2012)](https://doi.org/10.1007/s12603-012-0083-3)
[Pawelzik et al., Ketogenic diet in Parkinson's disease (2022) (2022)](https://doi.org/10.1002/mds.29065)
[Cunnane et al., Brain energy metabolism in AD (2020) (2020)](https://doi.org/10.1016/j.tics.2020.01.011)
[Van der Auwera et al., Ketogenic diet effects on neurodegeneration (2005) (2005)](https://doi.org/10.1016/j.neurobiolaging.2005.03.010)
[Freeman et al., Ketogenic diet in neurological disorders (2014) (2014)](https://doi.org/10.1016/S1474-4422(14)
[Mattson et al., Energy intake and excitability (2018) (2018)](https://doi.org/10.1016/j.neuron.2018.01.008)
Unknown, NCT03963206 Clinical Trial (n.d.)
[Phillips et al., Low-carbohydrate diets for AD (2018) (2018)](https://doi.org/10.1186/s13195-018-0395-5)
[Taylor et al., Metabolic therapy for PD (2021) (2021)](https://doi.org/10.1002/mds.28466)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Show full description